Cerebral Blood Flow & PETCO2 on Neuromuscular Function During

Status Completed

Clinical Trial Summary

Environmental stress, such as low oxygen availability (hypoxia), has been associated with impaired neuromuscular performance; however, the mechanisms associated with these performance decrements remain unclear. While the majority of research suggests that the observed fatigue is related to the central nervous system, the influence of changes in cerebral blood flow (CBF) and associated changes in cerebral pH (partial pressure of carbon dioxide; PCO2) remains unexamined. In response to hypoxic stress, humans hyperventilate to maintain oxygen consumption, resulting in a hypocapnia mediated decrease in CBF and cerebral alkalosis (decreased PCO2). Previous research suggests that hyperventilation induces changes in neural excitability and synaptic transmission; however, it remains unclear if these changes are related to hypocapnia mediated decrease in CBF or cerebral alkalosis or both.

The purpose of the proposed research program is to examine the influence of changes in CBF and cerebral alkalosis on neuromuscular function during environmental stress. The research program will consist of 2 separate projects, summarized below in a table outlining the proposed protocols and resultant physiological manipulations. During each manipulation, neuromuscular function will be evaluated and compared to baseline (normoxic) conditions using a repeated measures design.

The research program will consist of 2 separate projects. Project 1 will examine the changes in CBF and alkalosis by using (a) indomethacin (decrease CBF; no change PCO2) and (b) hypocapnia (decrease CBF; decrease PCO2). Using a similar experimental design, Project 2 will examine the change in CBF and alkalosis during hypoxia by using (a) poikilocapnic hypoxia (decrease PO2; decrease CBF; decrease PCO2), (b) isocapnic hypoxia (decrease PO2; no change CBF; no change PCO2) and (c) isocapnic hypoxia + indomethacin (decrease PO2; decrease CBF; no change PCO2). During each manipulation, neuromuscular function will be evaluated and compared to baseline (normoxic) conditions using a repeated measures design.

Therefore, Project 1 will examine the separate and combined effect of changes in CBF and cerebral alkalosis on neuromuscular function independent of environmental manipulations. Subsequently, Project 2 will examine neuromuscular function during hypoxia while controlling CBF and cerebral alkalosis. It is hypothesized that changes in PCO2 and therefore, changes in cerebral alkalosis will contribute to neuromuscular fatigue independent of changes in CBF and oxygen availability.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01830335
Study type	Interventional
Source	Brock University
Contact
Status	Completed
Phase	Phase 4
Start date	April 2013
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04234594` - Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.	Phase 1
Completed	`NCT01367561` - Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function	Phase 1
Completed	`NCT00777543` - Increasing Ferulic Acid Bioavailability in Bran	N/A
Recruiting	`NCT04756635` - Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity	N/A
Completed	`NCT01848665` - The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress	Phase 4
Completed	`NCT02156661` - Oxytocin and Emotion Processing	Phase 1
Completed	`NCT05294198` - Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males	N/A
Completed	`NCT00839319` - HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone	Phase 1/Phase 2
Completed	`NCT00842751` - Oral T7 Oral Testosterone in Man	Phase 2
Completed	`NCT01847053` - Bioavailability Study of Cinnamon in Healthy Subjects	Phase 1/Phase 2
Completed	`NCT01215292` - ITT4 Intratesticular Hormonal Milieu in Man (ITT4)	Phase 1/Phase 2
Completed	`NCT00782392` - Bioavailability and Dosing of a Monosaccharide Supplement in Adults	N/A
Completed	`NCT03714685` - Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations	Phase 1
Completed	`NCT05277597` - Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota	N/A
Completed	`NCT01032616` - Uptake and Utilization of Amino Acids by Splanchnic Bed	Phase 1
Completed	`NCT00902512` - Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations	Phase 4
Completed	`NCT00475371` - A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males	Phase 1
Completed	`NCT01870102` - Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms